Drug-drug interactions between clopidogrel and novel cardiovascular drugs

European Journal of Pharmacology
Francesco PellicciaDominick J Angiolillo

Abstract

The combination of aspirin and the thienopyridine clopidogrel is a cornerstone in the prevention of atherothrombotic events. These two agents act in concert to ameliorate the prothrombotic processes stimulated by plaque rupture and vessel injury complicating cardiovascular disease. Guidelines recommend the use of clopidogrel in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention, and the drug remains the most utilized P2Y12 receptor inhibitor despite the fact that newer antiplatelet agents are now available. In recent years, numerous studies have shown inconsistency in the efficacy of clopidogrel to prevent atherothrombotic events. Studies of platelet function testing have shown variability in the response to clopidogrel. One of the major reason for this phenomenon lies in the interaction between clopidogrel and other drugs that may affect clopidogrel absorption, metabolism, and ultimately its antiplatelet action. Importantly, these drug-drug interactions have prognostic implications, since patients with high on-treatment platelet reactivity associated with reduced clopidogrel metabolism have an increased risk of ischemia. Previous systematic reviews have focused on drug-drug intera...Continue Reading

References

Dec 18, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Thomas A Clarke, Lucy A Waskell
Nov 13, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN CAMELOT Investigators
Aug 1, 2006·American Heart Journal·Steven R Steinhubl, W Scott Akers
Mar 6, 2007·Thrombosis and Haemostasis·Jolanta Siller-MatulaKurt Huber
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Nov 15, 2008·Journal of the American College of Cardiology·Jolanta M Siller-MatulaBernd Jilma
Dec 25, 2008·The New England Journal of Medicine·Tabassome SimonUNKNOWN French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators
Aug 19, 2009·Heart·Thomas GremmelChristoph W Kopp
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Mar 12, 2011·Journal of the American College of Cardiology·Eric R BatesDominick J Angiolillo
Jan 17, 2012·British Journal of Clinical Pharmacology·Morten SchmidtHenrik Toft Sørensen
Oct 1, 2013·Journal of the American College of Cardiology·Udaya S TantryUNKNOWN Working Group on On-Treatment Platelet Reactivity
Jan 7, 2014·Circulation Journal : Official Journal of the Japanese Circulation Society·Francesco PellicciaCarlo Gaudio
Jun 12, 2014·Postgraduate Medicine·David A JohnsonHarley R Liker
Jul 12, 2014·European Journal of Clinical Pharmacology·Jean-Philippe ColletUNKNOWN DOSAPI investigators
Apr 8, 2015·Therapeutics and Clinical Risk Management·Zhi-Yu WangQuan Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Related Papers

Reviews in Cardiovascular Medicine
Luca FiletiMarco Valgimigli
Expert Review of Cardiovascular Therapy
Masafumi UenoDominick J Angiolillo
Journal of Cardiovascular Translational Research
Paul W A Janssen, J M ten Berg
© 2021 Meta ULC. All rights reserved